In the interest of public health, authorisation decisions under the centralised procedure should be taken on the basis of the objective scientific criteria of quality, safety and efficacy of the medicinal product concerned, to the exclusion of economic and other considerations. However, Member States should be able exceptionally to prohibit the use in their territory of medicinal products for human use which infringe objectively defined concepts of public policy and public morality. Moreover, a veterinary medicinal product is not to be authorised by the Community if its use would contravene the rules laid down within the framework of the Common Agricultural Policy or if presented for a use prohibited under other Community provisions, inter alia Directive 96/22/EC(8).
Recital 13, Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…
In forcesince 31 Mar 2004cited 2×
Judgment of the Court (Fourth Chamber), 11 April 2013. Novartis Pharma GmbH v Apozyt GmbH.Decision
Recitals 7 and 13 in the preamble to Regulation No 726/2004 read as follows: Experience gained since the adoption of Council Directive 87/22/EEC of 22 December 1986 on the approximation of national measures relating to the placing on the …
11 Apr 2013 · 62011CJ0535
Opinion of Advocate General Sharpston delivered on 31 January 2013. Novartis Pharma GmbH v Apozyt GmbH.Decision
Both Directive 2001/83 and Regulation No 726/2004 are drafted with a view to ensuring the safety of medicinal products. They are not concerned with economic factors, a point which is reinforced in recital 13 in the preamble to the …
31 Jan 2013 · 62011CC0535